Neurotech International Limited

Equities

NTI

AU000000NTI9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:56 2024-05-28 EDT			5-day change	1st Jan Change
0.073 ^AUD	-1.35%		-2.67%	+5.80%

04-17	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
04-17	Neurotech International Completes AU$10 Million Capital Raise	MT

Neurotech International Limited Appoints David Cantor to the Board as Non-Executive Director

July 03, 2018 at 06:28 pm

Neurotech International Limited announced the appointment of Dr. David Cantor to the board as a Non-Executive Director. Dr. Cantor's is currently the CEO and Clinical Director of Mind and Motion Developmental Centers of Georgia.

Latest news about Neurotech International Limited

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	04-17	MT
Neurotech International Completes AU$10 Million Capital Raise	04-16	MT
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	04-09	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	02-12	MT
Neurotech's ASD Drug Trials Exceed 90 Weeks	02-07	MT
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	01-28	MT
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	12-19	MT
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	12-04	MT
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	11-14	MT
Neurotech International Completes Enrollment for Rett Syndrome Trial	23-09-26	MT
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	23-08-30	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	23-07-10	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	23-05-30	MT
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	23-05-03	MT
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	23-03-20	MT
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	23-03-19	CI
Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%	23-03-16	MT
Neurotech International Limited Announces the Final Clinical Results from Eleven Paediatric Autism Spectrum Disorder Patients, Following Daily Treatment of NTI164 over 52 Week Period	23-03-16	CI
Neurotech International Halts Trade Pending Release of Clinical Trial Data	23-03-15	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial	23-02-15	CI
Neurotech International Secures Ethics Approval to Extend Phase 1/2 Autism Trial	23-02-14	MT
Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension	23-02-13	CI

Chart Neurotech International Limited

Duration

Period

More charts

Company Profile

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROTECH INTERNATIONAL LIMITED	+5.80%	50.12M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research